On a contract basis between October 1, 2026 and October 31, 2026, the Company acquired 18,100 shares of its common stock for a total of 69,273,000 yen. The acquisitions were implemented through an entrusted trading agreement and off-auction purchases. At the Board of Directors meeting on May 11, 2026, a cap of 1,300,000 shares and an upper limit of 6,000,000,000 yen were established; as of October 31, 2026, cumulative acquisitions total 200,000 shares for a total of 799,311,500 yen.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"price_fetched_at":"","company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4547","jir_company_name":"Kissei Pharmaceutical Co., Ltd.","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-11-04","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/11\/4547-20261104-04.pdf","jir_short_summary":"On a contract basis between October 1, 2026 and October 31, 2026, the Company acquired 18,100 shares of its common stock for a total of 69,273,000 yen. The acquisitions were implemented through an entrusted trading agreement and off-auction purchases. At the Board of Directors meeting on May 11, 2026, a cap of 1,300,000 shares and an upper limit of 6,000,000,000 yen were established; as of October 31, 2026, cumulative acquisitions total 200,000 shares for a total of 799,311,500 yen.","jir_summary":"### Transaction Overview\nDuring the period, Kissei Pharmaceutical Co., Ltd. acquired 18,100 shares of its common stock through market purchases of treasury stock. The total acquisition cost amounted to 69,273,000 yen, and the acquisitions were executed using a combination of an entrusted trading agreement on listed markets and off-auction purchases. These were implemented within the framework approved by the Board of Directors on May 11, 2026, which set an upper limit of 1,300,000 shares and an upper monetary limit of 6,000,000,000 yen. Cumulatively, as of October 31, 2026, 200,000 shares have been acquired for a total of 799,311,500 yen.\n\n### Background and Outlook\nThe share buyback is aimed at shareholder returns and improvement of capital efficiency. The Company intends to continue acquiring shares at appropriate timings while monitoring market conditions. Based on the approved upper limits and current cumulative results, whether additional acquisitions occur and the timing thereof will depend on market trends.","jir_financial_highlights":"Total number of shares acquired: 18,100 shares (Unknown)\nTotal acquisition cost: 69,273,000 yen (Unknown)\nPeriod: 2026-10-01\uff5e2026-10-31 (contract basis) (Unknown)\nCumulative number of shares acquired (as of 2026-10-31): 200,000 shares (Unknown)\nCumulative acquisition cost (as of 2026-10-31): 799,311,500 yen (Unknown)","jir_category":"","jir_hashtags":"#KisseiPharmaceutical, #ShareBuyback","jir_key_figures":"Total number of shares acquired: 18,100 shares\nTotal acquisition cost: 69,273,000 yen\nCumulative number of shares acquired: 200,000 shares","jir_meta_title":"Kissei Pharmaceutical Co., Ltd. \u2013 Notice on Treasury Stock Acquisition Status | November 2026","jir_meta_description":"Summary of Kissei Pharmaceutical Co., Ltd.'s treasury stock acquisitions, including number of shares acquired, total amount, period and cumulative results, and the Company's future acquisition policy.","jir_og_title":"Kissei Pharmaceutical Co., Ltd. \u2013 Notice on Treasury Stock Acquisition Status | November 2026","jir_og_description":"Clear summary of the treasury stock acquisition period and cumulative results, with commentary on shareholder return considerations.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":8930,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"share_buyback","footnotes":""},"sector":[],"importance":[],"class_list":["post-141388","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n